Are you at risk for colorectal cancer? Answer these 13 questions in less than 1 minute to find out.
Our Clinical Trial Finder is a one-stop place to find and learn more about high-impact research studies for patients with advanced CRC. The current data is now for metastatic, stage IV patients with both MSS and MSI-H status.
Our Path to a Cure report is our plan for the future. This plan is not just for Fight CRC, but for everyone who is willing to champion this cause.
Shop our online store to raise awareness everywhere you go! From t-shirts and fanny packs to patient education resources, we have a little bit of everything.
Raise Awareness. Be an Advocate. Host an Event.
Program Status Clinical trial’s patient recruitment status
Phase Phase of the clinical trial that is recruiting (I, II, or III)
Immunotherapy-centered Trial A flag to indicate whether the trial is an immunotherapy trial
Prior Immunotherapy Allowed Whether the clinical trial is open to patients who have received prior immunotherapy
CRC-directed Trial A flag to indicate whether the trial is specifically targeting colon cancer, rectal cancer, or colorectal cancer patients
Drugs Therapeutics used in the clinical trial
Tags
Comments
Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination With Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558, Opdivo)
Inclusion Criteria
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria:
Must have histologic or cytologic confirmation of an incurable solid malignancy that is advanced (metastatic and/or unresectable) Must have received, and then progressed or been intolerant to, standard treatment regimen in the advanced or metastatic setting, if such a therapy exists Presence of at least one lesion with measurable disease as defined by RECIST v1.1 criteria for response assessment Males and Females, ages 20 years or older, inclusive
Exclusion Criteria
Exclusion Criteria:
Known or suspected CNS (central nervous system) metastases or with the CNS as the only site of active disease Other concomitant malignancies (with some exceptions per protocol) Any active autoimmune disease or history of known or suspected autoimmune disease History of uncontrolled or significant cardiovascular disease
Other protocol defined inclusion/exclusion criteria could apply
NCT ID Trial ID number from clinicaltrials.gov or other database
Date Trial Added Date on which the clinical trial was added to the clinicaltrials.gov website
Updated Date Date on which the clinical trial was updated on the clinicaltrials.gov website